ABBOTT LABORATORIES Retained Earnings
ABBOTT LABORATORIES (ABT) had Retained Earnings of $49.96 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-04-29
- 2026-03-31: Retained Earnings (Accumulated Deficit) $49.96B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) $49.78B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) $49.10B.
- 2025-06-30: Retained Earnings (Accumulated Deficit) $48.47B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-03-31 | $49.96B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $49.78B 10-Q · filed 2026-04-29 | |
| 2025-09-30 | $49.10B 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $48.47B 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $47.72B 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $47.26B 10-K · filed 2026-02-20 | |
| 2024-09-30 | $39.06B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $38.35B 10-Q · filed 2024-07-31 | |
| 2024-03-31 | $38.01B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $37.55B 10-K · filed 2025-02-21 | |
| 2023-09-30 | $36.92B 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $36.35B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $35.87B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $35.26B 10-K · filed 2024-02-16 | |
| 2022-09-30 | $35.12B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $34.49B 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $33.30B 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $31.53B 10-K · filed 2023-02-17 | |
| 2021-09-30 | $30.38B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $29.05B 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $28.67B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $27.63B 10-K · filed 2022-02-18 | |
| 2020-09-30 | $26.27B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $25.67B 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $25.79B 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $25.85B 10-K · filed 2021-02-19 | |
| 2019-09-30 | $25.44B 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $25.05B 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $24.61B 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $24.56B 10-K · filed 2020-02-21 | |
| 2018-09-30 | $24.14B 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $24.08B 10-Q · filed 2018-08-01 | |
| 2018-03-31 | $23.86B 10-Q · filed 2018-05-02 | |
| 2017-12-31 | $23.98B 10-K · filed 2019-02-22 | |
| 2017-09-30 | $25.32B 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $25.20B 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $25.39B 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $25.57B 10-K · filed 2018-02-16 | |
| 2016-09-30 | $25.16B 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $25.88B 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $25.65B 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $25.76B 10-K · filed 2017-02-17 | |
| 2015-09-30 | $25.38B 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $25.16B 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $24.74B 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $22.87B 10-K · filed 2016-02-19 | |
| 2014-09-30 | $22.34B 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $22.14B 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $22.00B 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $21.98B 10-K · filed 2015-02-27 | |
| 2013-09-30 | $21.67B 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $20.32B 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $20.06B 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $24.15B 10-K · filed 2014-02-21 | $24.15B 10-K · filed 2013-02-15 |
| 2012-09-30 | $23.33B 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $22.23B 10-Q · filed 2012-08-07 | |
| 2012-03-31 | $21.31B 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $20.91B 10-K · filed 2013-02-15 | |
| 2011-09-30 | $20.05B 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $20.51B 10-Q · filed 2011-08-04 | |
| 2011-03-31 | $19.32B 10-Q · filed 2011-05-06 | |
| 2010-12-31 | $19.22B 10-K · filed 2013-02-15 | $18.93B 10-K · filed 2011-02-18 |
| 2010-09-30 | $18.18B 10-Q · filed 2010-11-05 | |
| 2010-06-30 | $17.98B 10-Q · filed 2010-08-05 | |
| 2010-03-31 | $17.37B 10-Q · filed 2010-05-04 | |
| 2009-12-31 | $17.34B 10-K · filed 2012-02-21 | $17.05B 10-K · filed 2010-02-19 |
| 2009-09-30 | $16.15B 10-Q · filed 2009-11-06 | |
| 2009-06-30 | $15.30B 10-Q · filed 2009-08-07 | |
| 2008-12-31 | $13.83B 10-K · filed 2011-02-18 | |
| 2007-12-31 | $10.81B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |